Invitational Awards

CURRENT INVITATIONAL FUNDS

Internal applications must include the following information:

  • One page cover letter that includes the name, title, and department of the lead investigator
  • Letter of support from the Division Chief or Department Chair
  • Summary of the proposed project (2-page limit not including references)
  • Biosketch of each major investigator including current and pending support in NIH format

 

The Experimental Therapeautics Clinical Trials Network (UM1 Clinical Trial Required)

*Limited Submission* NIH funding opportunity
BRI Internal Application Deadline: April 8, 2019
NIH Deadline: May 22, 2019
Indirect Overhead Rate: Full NIH rate
# of BWH nominations: 1
Summary: The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to continue support for the Experimental Therapeutics Clinical Trials Network (ETCTN) for the efficient and comprehensive conduct of early phase clinical trials of NCI Investigational New Drug (IND) agents. The ETCTN is designed to assure the availability of investigators and programs with expertise in early drug development and translational research for this purpose. This FOA solicits UM1 cooperative Limited Submission Funding Opportunities – updated 3/22/19 agreement applications from appropriate multidisciplinary groups that can assemble an appropriate infrastructure and conduct phase 0, phase 1, phase 2, pilot and other experimental therapeutics clinical trials involving agents for which the NCI’s Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP) received IND status. The FOA is open to any qualified applicant regardless of whether they have been previously associated with the ETCTN. 2. The Experimental
*Limited Submission* NIH funding opportunity
BRI Internal Application Deadline: April 8, 2019
NIH Deadline: May 22, 2019
Indirect Overhead Rate: Full NIH rate
# of BWH nominations: 1
Summary: The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratories is to advance the clinical development of NCI-IND agents through achieving comprehensive understanding of pharmacokinetic behavior of these agents studied in ETCTN protocols. The ETCTN Pharmacokinetic Resource Laboratories will assure the availability of physicians, clinical pharmacologists, nurses and scientists who have the appropriate expertise in pharmacokinetic studies for early drug development and translational research. This FOA seeks U24 cooperative agreement applications from multidisciplinary groups that will conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to the IND applications in NCI’s Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).

 

ADA Pathway to Stop Diabetes Awards 2019 
American Diabetes Association
Amount: up to $1,625,000 over 5-7 years
Deadline: April 1, 2019 (internal application)
Indirect Overhead Rate: Between 10% and 30% – see funding details below. When necessary, BWH will cover the difference to meet the 15% IDC minimum.

# of BWH nominations: 1
Internal Submission Portal: http://bwhcfdd.partners.org/Listing.aspx?courseId=423

 

Only ONE application to ONE ADA Pathway Award will be accepted from each BWH department (or division within the Department of Medicine) to be considered as the BWH nominee. Please seek approval from your department chair or division chief before submitting your application.

Program Description:

Pathways awards seek to bring new investigators and new perspectives to diabetes research. Supporting scientists with different backgrounds and experience is critical to achieving that objective. Pathway accepts nominations for exceptional investigators with medical and scientific backgrounds who propose innovative basic, clinical, translational, behavioral, epidemiological and health services research relevant to any type of diabetes, diabetes-related disease state or complication. Pathway solicits nominations for candidates in all disciplines as applied to diabetes including medicine, biology, chemistry, computing, physics, mathematics and engineering. In addition, nomination of scientists from diverse backgrounds, including minority groups that are underrepresented in biomedical research, is strongly encouraged.

 

 

Translational Cancer Research Grant Program 

V Foundation (link to https://www.jimmyv.org/)
Amount: $600,000 over 3 years
Deadline: April 1, 2019 (internal application)
Indirect Overhead Rate: 10% from the foundation, BWH will provide the remaining 5% to meet the 15% minimum

# of BWH nominations: 1
Internal Submission Portal: http://bwhcfdd.partners.org/Listing.aspx?courseId=421

The V Foundation seeks to support translational research projects within the scope of adult cancer research. Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.

Only ONE internal application from each Department (or Division with in the Dept. of Med.) will be considered for nomination to apply for this limited submission award – please coordinate with your Chair or Chief.

PAST INVITATIONAL FUNDS

X